Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or...